Predictors of major bleeding in acute coronary syndromes:: the Global Registry of Acute Coronary Events (GRACE)

被引:745
作者
Moscucci, M
Fox, KAA
Cannon, CP
Klein, W
López-Sendón, J
Montalescot, G
White, K
Goldberg, RJ
机构
[1] Univ Michigan Hlth Syst, Ann Arbor, MI USA
[2] Univ Edinburgh, Royal Infirm Edinburgh, Edinburgh EH3 9YW, Midlothian, Scotland
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Graz Univ, Med Klin, A-8036 Graz, Austria
[5] Univ Madrid, Hosp Gen Gregorio Maranon, Madrid, Spain
[6] Hop La Pitie Salpetriere, Paris, France
[7] Univ Massachusetts, Sch Med, Worcester, MA USA
关键词
major bleeding; acute coronary syndromes; complications; myocardial infarction; unstable angina;
D O I
10.1016/S0195-668X(03)00485-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims There have been no large observational studies attempting to identify predictors of major bleeding in patients with acute coronary syndromes (ACS), particularly from a multinational perspective. The objective of our study was thus to develop a prediction rule for the identification of patients with ACS at higher risk of major bleeding. Methods and results Data from 24045 patients from the Global Registry of Acute Coronary Events (GRACE) were analysed. Factors associated with major bleeding were identified using logistic regression analysis. Predictive models were developed for the overall patient population and for subgroups of patients with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The overall incidence of major bleeding was 3.9% (4.8% in patients with STEMI, 4.7% in patients with NSTEMI and 2.3% in patients with unstable angina). Advanced age, female sex, history of bleeding, and renal insufficiency were independently associated with a higher risk of bleeding (P<0.01). The association remained after adjustment for hospital therapies and performance of invasive procedures. After adjustment for a variety of potential confounders, major bleeding was significantly associated with an increased risk of hospital death (adjusted odds ratio 1.64, 95% confidence interval 1.18, 2.28). Conclusions In routine clinical practice, major bleeding is a relatively frequent non-cardiac complication of contemporary therapy for ACS and it is associated with a poor hospital prognosis. Simple baseline demographic and clinical characteristics identify patients at increased risk of major bleeding. (C) 2003 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
引用
收藏
页码:1815 / 1823
页数:9
相关论文
共 39 条
  • [1] [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105, DOI DOI 10.1016/0895-4356(88)90084-4
  • [2] TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: A double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods
    Antman, EM
    [J]. AMERICAN HEART JOURNAL, 1998, 135 (06) : S353 - S360
  • [3] Bazzino O, 1998, NEW ENGL J MED, V338, P1488
  • [4] Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction
    Berkowitz, SD
    Granger, CB
    Peiper, KS
    Lee, KL
    Gore, JM
    Simoons, M
    Armstrong, PW
    Topol, EJ
    Califf, RM
    [J]. CIRCULATION, 1997, 95 (11) : 2508 - 2516
  • [5] Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes -: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
    Boersma, E
    Akkerhuis, KM
    Théroux, P
    Califf, RM
    Topol, EJ
    Simoons, ML
    [J]. CIRCULATION, 1999, 100 (20) : 2045 - 2048
  • [6] HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL
    BOVILL, EG
    TERRIN, ML
    STUMP, DC
    BERKE, AD
    FREDERICK, M
    COLLEN, D
    FEIT, F
    GORE, JM
    HILLIS, LD
    LAMBREW, CT
    LEIBOFF, R
    MANN, KG
    MARKIS, JE
    PRATT, CM
    SHARKEY, SW
    SOPKO, G
    TRACY, RP
    CHESEBRO, JH
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (04) : 256 - 265
  • [7] Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in myocardial ischemia, phase IIIB trial)
    Bovill, EG
    Tracy, RP
    Knatterud, GL
    Stone, PH
    Nasmith, J
    Gore, JM
    Thompson, BW
    Tofler, GH
    Kleiman, NS
    Cannon, C
    Braunwald, E
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (04) : 391 - 396
  • [8] Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin
    Busby, LT
    Weyman, A
    Rodgers, GM
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2001, 67 (01) : 54 - 56
  • [9] DELAYED ELIMINATION OF ENOXAPARINE IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY
    CADROY, Y
    POURRAT, J
    BALADRE, MF
    SAIVIN, S
    HOUIN, G
    MONTASTRUC, JL
    VERNIER, I
    BONEU, B
    [J]. THROMBOSIS RESEARCH, 1991, 63 (03) : 385 - 390
  • [10] HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH THE USE OF INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR IN TREATMENT OF ACUTE MYOCARDIAL-INFARCTION
    CALIFF, RM
    TOPOL, EJ
    GEORGE, BS
    BOSWICK, JM
    ABBOTTSMITH, C
    SIGMON, KN
    CANDELA, R
    MASEK, R
    KEREIAKES, D
    ONEILL, WW
    STACK, RS
    STUMP, D
    [J]. AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) : 353 - 359